{'fraction_non_alphanumeric': 0.018083182640144666, 'fraction_numerical': 0.0, 'mean_word_length': 5.367816091954023, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effect of concomitant therapy on adynamic bone disease].

PTH deficiency and/or skeletal resistance to PTH in uremia has been regarded the major cause of adynamic bone. Considering the pathogenesis, correction of hypercalcemia is the first management to increase PTH secretion. For that purpose administrating regimen of calcium-containing phosphate binder and active vitamin D sterols should be changed to prevent hypercalcemia. And it is also important to determine an adequate calcium concentration of dialysate for the stimulation of PTH secretion.